Particle Sciences enters licensing, technology agreement with Solubest

Particle Sciences Inc. (PSI), a leading pharmaceutical CRO and SoluBest have entered into a licensing and technology development agreement.  Under the agreement, Particle Sciences will be the exclusive contract research provider in the U.S. for SoluBest's Solumer technology.  Particle Sciences will offer Solumer formulation and clinical trial supply manufacturing to Pharmaceutical and Biotech companies.  The patented Solumer approach utilizes GRAS polymers to create drug/polymer complexes that result in greatly improved drug solubility and bioavailability.  Once formulations come in contact with aqueous media, they spontaneously form colloidal dispersions, resulting in increased bioavailability of the active pharmaceutical ingredient.  The process is easily adaptable to a wide range of molecules, making it attractive for both new chemical entities and life-cycle management challenges.

According Amir Zalcenstein, SoluBest's CEO, "We are thrilled to partner with Particle Sciences.  They are at the cutting edge of drug delivery technologies and provide us with greater access to the U.S. marketplace.  Additionally, by leveraging their significant GMP/GLP infrastructure, we are able to offer potential licensees a clear development path with a world-class CRO. Moreover, following our recent licensing deal with Dr. Reddy's, we're seeing a lot of interest in our technology, and partnering with Particle Sciences is essential in order to meet the increased demand."

Mark Mitchnick, CEO of Particle Sciences adds, "The Solumer technology fits perfectly with our growth strategy of adopting truly value added drug delivery approaches to our portfolio.  This is a proven technology that is both cost effective and scalable.  It will find application with both NCE's and generics.  Under this agreement, Particle Sciences will use Solumer technology to develop drug products for our clients.  We are very excited to be working with SoluBest and are already evaluating the technology for specific projects."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024